What is Progyny?
Founded in 2008 and headquartered in New York City, Progyny operates as a leading fertility benefits management company in the United States. It specializes in offering comprehensive fertility and family-building benefit solutions through a unique platform. This platform connects patients with premier fertility specialists and advanced reproductive technologies, while simultaneously managing costs for employers. Progyny's integrated approach includes patient education, dedicated advocacy support, and access to a curated network of fertility experts, all designed to improve clinical outcomes and make fertility treatments more accessible and cost-effective. The company's vision is to broaden access to fertility care for all individuals seeking to build a family, leveraging both mobile app support and B2B services within the insurance industry.
How much funding has Progyny raised?
Progyny has raised a total of $131.8M across 4 funding rounds:
Series A
$20M
Series B
$14.7M
Other Financing Round
$10M
Stock Offering
$87.1M
Series A (2012): $20M with participation from Kleiner Perkins Caufield and Byers, Merck Serono Ventures, and TPG Biotech
Series B (2016): $14.7M led by M Ventures, TPG Biotech, SR One, Kleiner Perkins Caufield and Byers, Mellon Ventures, and Union Grove Venture Partners
Other Financing Round (2017): $10M supported by TPG Biotech, SR One, and Kleiner Perkins Caufield and Byers
Stock Issuance/Offering (2019): $87.1M, investors not publicly disclosed
Key Investors in Progyny
TPG Biotech
TPG Biotech is a global investment firm focused on managing alternative assets and supporting business growth across diverse industries. It provides investment management, advisory, and capital solutions, operating across private equity, credit, and real estate to help organizations expand and improve performance.
SR One
SR One is a transatlantic venture capital firm specializing in early and growth-stage life sciences companies developing novel therapeutics. The firm partners with founders to translate innovative technologies into new medicines, providing strategic and operational support.
Kleiner Perkins Caufield and Byers
Kleiner Perkins is a venture capital firm that invests in early and growth-stage technology and life science companies. They back founders from seed through IPO or acquisition, offering capital and operational support.
What's next for Progyny?
The recent major strategic investment in Progyny, following substantial enterprise-level funding, indicates a strong trajectory for scaling its operations and market penetration. This capital infusion is likely to fuel further development of its technology platform, expansion into new employer markets, and enhancement of its patient support services. As Progyny continues to solidify its position in the rapidly evolving landscape of employer-sponsored healthcare benefits, its focus on improving fertility care access and outcomes is expected to drive continued innovation and growth, potentially positioning the company for further strategic partnerships or market consolidation.
See full Progyny company page
